Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Pituitary Neoplasms × Capecitabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 113 Colorectal Neoplasms 73 Stomach Neoplasms 47 Pancreatic Neoplasms 45 Rectal Neoplasms 40 Neoplasms 29 Neoplasm Metastasis 29 Colonic Neoplasms 18 Esophageal Neoplasms 16 Triple Negative Breast Neoplasms 13 Adenocarcinoma 11 Parkinson Disease 4, Autosomal Dominant Lewy Body 9 Gallbladder Neoplasms 9 Bile Duct Neoplasms 8 Brain Neoplasms 7 Adenocarcinoma Of Esophagus 7 Liver Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Cholangiocarcinoma 5 Breast Neoplasms, Male 5 Somatostatinoma 4 Head and Neck Neoplasms 4 Carcinoma, Hepatocellular 4 Biliary Tract Neoplasms 4 Gastrointestinal Neoplasms 3 Gastrinoma 3 Esophageal Squamous Cell Carcinoma 3 Carcinoma, Squamous Cell 3 Carcinoma, Renal Cell 3 Solid Tumor 2

Interventions

pasireotide 7 Cabergoline 2 lanreotide 1 Thyrotropin-Releasing Hormone 1 Temozolomide 1 Rosiglitazone 1 Lapatinib 1 Ibuprofen 1 Hydrocortisone 1 Dexamethasone 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03930771 2022-08-09

TMZ-Cap

Weill Medical College of Cornell University

Phase 2 Terminated

1 enrolled 8 charts

Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡